Late-breaking data highlighted the effectiveness of Boston Scientific’s (NYSE:BSX) S-ICD technology and Watchman FLX device. Multiple trials, for which data was presented at the Heart Rhythm Society (HRS) Heart Rhythm 2022 conference, backed Marlborough, Massachusetts-based Boston Scientific’s subcutaneous implantable cardiac defibrillators (S-ICD) against transvenous ICDs (TV-ICD) — and the Watchman FLX left atrial appendage closure […]